



CURRICULUM VITAE

Edward T. A. Fry, M.D., MACC, FSCAI, (Hon.) FRPCI

Office Address	Ascension-IN/St. Vincent Medical Group 10590 North Meridian Indianapolis, Indiana 46290 Office: 317-583-6046, Cell: 317-694-9555 Fax: 317-583-6273, email: etfry@ascension.org
Birth day	February 11, 1957
Birth Place	Dublin, Ireland
Citizenship	U. S., naturalized 1977
Marital Status	Married, three sons
Hobbies	Running, biking, hiking, gardening, music, travel

EDUCATION

Undergraduate	Grinnell College Grinnell, Iowa 1979 BA Chemistry, with honors
Medical School	Washington University School of Medicine St. Louis, Missouri 1983 MD

AWARDS

Phi Beta Kappa - 1979
 American Society of Chemists Award - 1979
 Merck Book Award -1983
 Indianapolis Monthly Top Docs – multiple years
 US New and World Reports – Top Doctors in U.S. - 2012

POSTDOCTORAL TRAINING

Residency	Internal Medicine Washington University School of Medicine St. Louis, Missouri 1983 – 1986
Fellowship	Cardiology Research Washington University School of Medicine St. Louis, Missouri Advisor: Burton Sobel, MD 1986 - 1988
Fellowship	Cardiology Washington University School of Medicine St. Louis, Missouri 1986 – 1990
Fellowship	Interventional Cardiology Nasser, Smith & Pinkerton Cardiology St. Vincent Hospital Indianapolis, Indiana 1991 - 1992

ACADEMIC APPOINTMENTS

Instructor, Advanced Cardiac Life Support
 Washington University School of Medicine
 St. Louis, Missouri
 1986 - 1987

Preceptor, Introduction to Clinical Medicine
 Washington University School of Medicine
 St. Louis, Missouri
 1986 – 1988

Clinical Instructor, Internal Medicine
 Washington University School of Medicine
 St. Louis, Missouri
 1990

Assistant Professor, Internal Medicine
 Washington University School of Medicine
 St. Louis, Missouri
 1990-1991

Medical Director, Cardiac Transplant Program
 Washington University School of Medicine
 St. Louis, Missouri
 1990 – 1991

Key Clinical Faculty, General and Interventional Cardiology
 Fellowship Training Program
 St. Vincent Hospital, Indianapolis, IN
 2003-present

Pre-Clinical and Clinical Faculty
 Marion University School of Medicine
 Indianapolis, IN
 2014 - Present

EMPLOYMENT HISTORY

Washington University School of Medicine, Div. of
 Cardiology. 1989 – 1991

Ascension-IN/St. Vincent Medical Group, 1991 - present
 (Group previously named: Nasser, Smith, and
 Pinkerton Cardiology, 1991-1999, The Care Group LLC,
 1999-2010)

HOSPITAL/HEALTH SYSTEM APPOINTMENTS

Director, Interventional Cardiology
 St. Vincent Heart Center of Indiana
 2002-2010

Chairman, Interventional Cardiology Continuous
 Quality Improvement Committee

St. Vincent Hospital
Indianapolis, IN
1996-2011

Co-Chairman, Cardiovascular Service Line Quality
Improvement Committee
St. Vincent Hospital, Indianapolis, IN
2005-2011

Chair, Ascension Health Interventional Cardiology
Affinity Group
Ascension Health
2009-2016

Chair, Cardiology Division
Ascension-IN/St. Vincent Medical Group
St. Vincent Health
2010-2021

Chair, Ascension Health National CV Service Line
Ascension Health
2015-Present

HOSPITAL AFFILIATIONS

Ascension/St. Vincent Heart Center of Indiana
Indianapolis, IN
2002 – present
Active

Ascension/St. Vincent Hospital and Health Care Center
Indianapolis, Indiana
1991- present
Active

Ascension/St. Vincent Kokomo Hospital
Kokomo, Indiana 1993 - present

Hendricks Regional Health
Danville, Indiana 1993 - present

Marion General Hospital

Marion, Indiana
 Courtesy 1993 - present

Ascension/St. Vincent Anderson Hospital
 Anderson, Indiana 1993- present
 Courtesy

Ascension/St. Vincent Women's Hospital
 Indianapolis, Indiana
 2004 - present
 Active

Ascension/St. Vincent Carmel Hospital
 Carmel, IN
 1991 – Present
 Active

Ascension/St. Vincent Northeast Hospital
 Fishers, IN
 2013 – Present
 Active

Ascension/St. Elizabeth Ann Seton Hospital
 Indianapolis, IN 1996 - present
 Active

Ascension/St. Vincent Jennings County Hospital
 North Vernon, IN
 2008 - Present
 Active

Ascension/St. Vincent Clay County Hospital
 Brazil, IN
 1999 – Present
 Consulting

Schneck Memorial Jackson County Hospital
 Seymour, IN
 2008 - present
 Consulting

LICENSURE AND BOARD CERTIFICATION

Indiana - active

American Board of Internal Medicine 1986
 American Board of Internal Medicine
 Subspecialty, Cardiovascular Disease 1989
 Maintenance of Certification (MOC) 2014 – Present
 American Board of Internal Medicine
 Subspecialty, Interventional Cardiology 1999
 (Recertified 2009, retired 2019)

PROFESSIONAL MEMBERSHIPS

1991 – present	American College of Cardiology, Fellow (FACC) American Medical Association Indiana State Medical Association Indianapolis Medical Society American Heart Association, Council on Clinical Cardiology Society of Angiography and Cardiology, FSCAI
2008 – present	American College of Cardiology, Indiana-Chapter Council Member
2010 – 2014	Steering Committee Mission Life Line - IN American Heart Association
2013 – 2016	American College of Cardiology Indiana-Chapter, President
2013-2016	American College of Cardiology Board of Governors
2013 – Present	American College of Cardiology (Committees): Digital Strategy Steering Committee Surviving MI Implementation Work Group

Clinical Quality Committee
 Integrating the Health Enterprise (IHE) Health Policy
 Work Group
 Clinical Quality Committee
 Prior Authorization Work Group
 ACC Telemedicine Project
 ACC Board of Governors
 ACC Board of Governors Steering Committee,
 Innovations Development Work Group
 ACC-Premier Oversight Work Group
 Clinician Well-being Task Force
 Health Systems Task Force,
 ACC HeartPAC
 ACC/AHA Ethics and Professionalism Consensus
 Task Force/Summit
 Nominating Committee (2019)
 Audit and Finance Committee (Chair)

2014 – 2016	Medicare/CMS Contractor Advisory Committee
2018 – 2024	American College of Cardiology, Trustee
2022 – 2023	American College of Cardiology, President
2023 – Present	American College of Cardiology, Master (MACC)
2023 – Present	Royal College of Physicians Ireland, (Hon.) Fellow (FRPCI)
2024 – Present	World Heart Federation, Chair, Audit Committee
2024 – Present	American Board of Cardiovascular Medicine, Trustee

JOURNAL REVIEWER

Circulation
 Coronary Artery Disease
 Blood
 American Journal of Cardiology
 Journal of Invasive Cardiology
 Catheterization and Cardiovascular Intervention

BOARD MEMBERSHIPS / DIRECTORSHIPS

The Care Group, LLC
Board of Managers, 2000 -2010

Gateway Medical Alliance, LLC
Board of Directors, 1998 -2006

Indiana Heart Institute,
Board of Directors, 2003 - 2010

Navion Healthcare Solutions, LLC.,
Board Chair, 2010 – 2017

St. Vincent Medical Group,
Cardiology, Managing Partner, 2010-2011

St. Vincent Medical Group,
Board Member, 2010 – 2017
Chair - 2017

Ascension-IN/St. Vincent Medical Group,
Chair, Cardiology Division, 2011 - 2020

Indiana Chapter of American College of Cardiology,
ACC Board of Governors
President, 2013 – 2016

American College of Cardiology
Board of Trustees, 2018 – 2024

MedAxiom
Board of Managers
2019 – 2021

American College of Cardiology
Vice President, 2021-2022
President 2022-2023
Immediate Past President 2023-2024

BIBLIOGRAPHY

PAPERS

1. **Fry ETA**, Sobel B.E. Lack of interference by heparin with thrombolysis or binding of tissue-type plasminogen activator to thrombi. *Blood* 71:1347-1352, 1988.
2. Lucore CL, **Fry ETA**, Nachowiak DA, Sobel BE. Biochemical determinants of clearance of tissue-type plasminogen activators from the circulation. *Circulation* 77:906-914, 1988.
3. Monge JC, Lucore CL, **Fry ETA**, Sobel BE, Billadello JJ. Characterization of active-site serine mutants of tissue-type plasminogen activator with plasminogen activator inhibitor-1. *J Biol Chem* 264:10922-10925, 1989.
4. **Fry ETA**, Grace AM, Sobel BE. Interactions between pharmacologic concentrations of plasminogen activators and platelets. *Fibrinolysis* 3:127136, 1989.
5. **Fry ETA**, Mack DL, Sobel BE. The nature of synergy between tissue-type and single chain urokinase-type plasminogen activators. *Thromb Haemost* 62:909-916, 1990.
6. **Fry ETA**, Sobel BE. Coronary thrombolysis (Review). *Prog Cardiol* 3:199239, 1990.
7. **Fry ETA**, Mack DL, Monge JC, Billadello JJ, Sobel BE. Labeling of human thrombi with an active site mutant of t-PA. *J Nucl Med* 30:187-191, 1990.
8. Sobel BE, Nachowiak DA, **Fry ETA**, Bergmann SR, Torr SR. Paradoxical attenuation of fibrinolysis attributable to 'plasminogen steal' and its implications for coronary thrombolysis. *Coronary Artery Disease* 1:111-119, 1990.
9. **Fry ETA**, Ludbrook PA. t-PA Update. Clinical promise realized. *Drug Therapy* 1990.
10. **Fry ETA**. Hemodynamic management of patients awaiting cardiac transplantation. Stabilization, optimization, and prevention of complications. *Coronary Artery Disease* 3:774-782, 1992.
11. Waller BF, Slack JD, Orr CM, Adlam JH, **Fry ETA**. Endomyocardial biopsy for evaluation, diagnosis and treatment of heart disease. *Am Coll Cardiol Curr J Rev* January/February:16-19, 1994.
12. **Fry ETA**, Hermiller JB, Peters TF, Orr CM, VanTassel J, Waller BF, Pinkerton CA. Indications for and applications of the Gianturco-Roubin Coronary Stent. *Cardiol Clin* 12:631-649, 1994.

13. Hermiller JB, **Fry ET**, Peters TF, Orr CM, VanTassel J, Waller B, Pinkerton CA. Late coronary artery stenosis regression within the Gianturco-Roubin intracoronary stent. *Am J Cardiol* 77:247-251, 1996.
14. Waller BF, **Fry ET**, Hermiller JB, Peters T, Slack JD. Nonatherosclerotic causes of coronary artery narrowing. Part I. *Clin Cardiol* 19:509-512, 1996.
15. Waller BF, **Fry ET**, Hermiller JB, Peters T, Slack JD. Nonatherosclerotic causes of coronary artery narrowing. Part II. *Clin Cardiol* 19:587-591, 1996.
16. Waller BF, **Fry ET**, Hermiller JB, Peters T, Slack JD. Nonatherosclerotic causes of coronary artery narrowing. Part III. *Clin Cardiol* 19:656-661, 1996.
17. Waller BF, Orr CM, VanTassel J, Peters T, **Fry ET**, Hermiller JB, Grider LD. Coronary artery and saphenous vein graft remodeling. A review of histologic findings after various interventional procedures. Part I. *Clin Cardiol* 19:744-748, 1996.
18. Waller BF, Orr CM, VanTassel J, Peters T, **Fry ET**, Hermiller JB, Grider LD. Coronary artery and saphenous vein graft remodeling. A review of histologic findings after various interventional procedures. Part II. *Clin Cardiol* 19:817-823, 1996.
19. Waller BF, Orr CM, VanTassel J, Peters T, **Fry ET**, Hermiller JB, Grider LD. Coronary artery and saphenous vein graft remodeling. A review of histologic findings after various interventional procedures. Part III. *Clin Cardiol* 19:895-901, 1996.
20. Waller BF, Orr CM, VanTassel J, Peters T, **Fry ET**, Hermiller JB, Grider LD. Coronary artery and saphenous vein graft remodeling. A review of histologic findings after various interventional procedures. Part IV. *Clin Cardiol* 19:960-966, 1996.
21. Waller BF, **Fry ETA**, Peters TF, Hermiller JB, Orr CM, VanTassel J, Pinkerton CA. Abrupt (1< day), acute (1< week), and early (<1 month) vessel closure at the angioplasty site. Morphologic observations and causes of closure in 130 necropsy patients undergoing coronary angioplasty. *Clin Cardiol* 19:857-868, 1996.
22. Waller BF, Orr CM, VanTassel J, Peters T, **Fry ET**, Hermiller JB, Grider LD. Coronary artery and saphenous vein graft remodeling. A review of histologic findings after various interventional procedures. Part V. *Clin Cardiol* 20:677-684, 1997.
23. Nasser TK, **Fry ETA**, Annan K, Khatib Y, Peters TF, VanTassel J, Orr CM, Waller BF, Pinto R, Pinkerton CA, Hermiller JB. Comparison of six-month outcome of coronary artery stenting in patients <65, 65-75, and >75 years of age. *Am J Cardiol* 80:998-1001, 1997.

24. **Fry ETA.** Re-administration of abciximab in percutaneous coronary intervention. *J Invasive Cardiol* 11(4):251-258, 1999
25. **Fry ETA.** Role of platelet glycoprotein IIb/IIIa receptor inhibitors in coronary intervention. Edited by Gibler WB, Ohman EM. *Current Use and Future Prospects for GP IIb/IIIa Inhibitors in the Treatment of Acute Coronary Syndromes*, 1999.
26. Hermiller James, **Fry, Edward**, Peters Thomas, Orr Charles, VanTassel James, Waller Bruce, Pinkerton Cass. Update on Management of In-Stent Restenosis. *J Interv Cardiol* 1998; 11(Suppl.):S51-S56.
27. Kereiakes Dean J, Grines Cindy, **Fry, Edward**, Esente Paola, Hoppensteadt Debra, Midei Mark, Barr Lawrence, Matthai William, Todd Mark, Broderick Thomas, Rubinstein Ronald, Fareed Jawad, Santoian Edward, Neiderman Alan, Brodie Bruce, Zidar James, Ferguson James, Cohen Marc,. *Enoxaparin and Abciximab Adjunctive Pharmacotherapy During Percutaneous Coronary Intervention*. *The Journal of Invasive Cardiology*; Volume 13 Number 4, April 2001
28. Batchelor Wayne MD, Mahaffey, Kenneth, Berger Peter, Deutsch Ezra Meier Susan, Hasselblad Vic, **Fry Edward T**, Teirstein Paul, Ross Allan, Binanay Cynthia, Zidar James. A Randomized, Placebo-controlled Trial of Enoxaparin after High-risk Coronary Stenting: the ATLAST Trial. *J. Am. Coll. Cardiol.* 2001;38:1608-13.
29. **Fry, Edward.** Glycoprotein IIb/IIIa Inhibitors and Low-Molecular-Weight Heparins: A Combined Role in Coronary Interventions? *Clinical Cardiology* 2001 Vol. 24 (Suppl.I) I-8
30. Kereiakes DJ, Kleinman Neal, **Fry Edward**, Mwawasi Grace, Lengerich Rose, Maresh Kelly, Burkert Mary Lynn, Aquilina, Joesph. Et al. Dalteparin in combination with abciximab during percutaneous coronary intervention. *Am Heart J* 2001;141:348-52
31. Steven Steinhubl,MD Peter Berger, MD, J Tift Mann, **Edward T.A. Fry**, Augustin DeLago, Charles Wilmer, Eric Topol. A Randomized, Double-Blind, Controlled Trial of Early and Sustained Dual Oral Anti-Platelet Therapy for Percutaneous Coronary Intervention. Results of the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial. *JAMA* 2002;288:2411-2420
32. Gideon Bosker, MD, Dean Kereiakes, MD, **Edward Fry, MD**, James Tchong, MD, *Acute Coronary Syndromes, Site Specialty and Spectrum of Care Strategies for Optimizing Patient Outcomes in NSTEMI-ACS and ST-Elevation Myocardial Infarction (STEMI)*. *Interventional Cardiology Consensus Reports*, May 1, 2003 Clinical Update.

33. Dean J. Kereiakes, MD, James Tchong, MD, **Edward T.A. Fry, MD**, Deepak L. Bhatt MD, Gideon Bosker, MD, Jose Diez, MD, James J. Ferguson, MD, James Zidar, MD-Pharmcoinvasive Management of Acute Coronary Syndrome in the Setting of Percutaneous Coronary Intervention: Evidence-Based, Site-and Sepctrum-of-Care Strategies for Optimizing Patient Outcomes in NSTEMI-ACS, *Journal of Invasive Cardiology* 2003;15:536-553
34. SYNERGY Investigators – Enoxaparin vs Unfractionated Heparin in High Risk patients with Non-ST-Segment Elevation Acute Coronary Syndromes Managed With an Intended Early Invasive Strategy. *JAMA* 2004;292:45-54.
35. Jack L. Martin, **Edward T.A. Fry**, Ger-Jan CM. Sanderink, Trevor Atherley, Colette Guimart, Paul J. Chevalier, Marie-Laure Ozoux, Catherine Pensyl, Frederique Bigonzi. Reliable Anticoagulation with Enoxaparin in Patients Undergoing Percutaneous Coronary Intervention: The Pharmacokinetics of Enoxaparin in PCI (PEPCI) Study. *Catheterization and Cardiovascular Interventions* 2004;61:163-170
36. Neil Sawhney, MD; Jeffrey W. Moses, MD; Martin B. Leon, MD; Richard E. Kuntz, MD; Jeffrey J. Popma, MD; William Bachinsky, MD; Theodore Bass, MD; Samuel DeMaio, MD; **Edward Fry, MD**; David R. Holmes, Jr, MD; Paul S. Teirstein, MD. Treatment of Left Anterior Descending Coronary Artery Disease With Sirolimus-Eluting Stents. *Circulation*. 2004;110:374-379.
37. Marc Cohen, MD, Jose Dez, MD, **Edward Fry, MD**, Sunil Rao, MD, James J. Ferguson III, MD, James Zidar, MD, Glenn Levine, MD, Jacob Shani, MD. Strategies for Optimizing Outcomes in the NSTEMI-ACS Patient: The CATH Clinical Consensus Panel Report. *Journal of Invasive Cardiology* 2006; 18:1-20.
38. Hermiller JB, **Fry ETA**, Peters TF, Pinkerton CA. Update on Management of In-Stent Restenosis. *J Intervent Cardiol* 2007;11(s5):S51-S56.
39. Cohen MG, Purdy DA, Rossi JS, Grinfeld LR, Myles SK, Aberle LH, Greenbaum AB, **Fry E**, Chan MY, Tonkens RM, Zelenkofske S, Alexander JH, Harrington RA, Rusconi CP, Becker RC. First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary Intervention. *Circulation* 2010;122:614-622.
40. Ito H, Taylor L, Bowman M, **Fry ETA**, Hermiller JB, Van Tassel JW. Presentation and Therapy of Spontaneous Coronary Artery Dissection and Comparisons of Postpartum Versus Non-postpartum Cases. 2011;107:1590-1596.
41. Eric N. Prystowsky, MD, **Edward Fry, MD**, Atrial Fibrillation and Incident Myocardial Infarction: *JAMA* 2014;312(10): 1049-1050. doi:10.1001/JAMA.2014.5742

42. Patrick T. O'Gara, MD, Chris Cooper, MD, and **Edward Fry, MD**. CV Workforce Projections Are Not What They Seem: Journal American College of Cardiology;2014;63(18):1927-1928. doi:10.1016/j.jacc.2014.04.002.
43. Windle JR, Katz AS, Dow J, **Fry ETA.**, et al. 2016 ACC/ASE/ASNC/HRS/SCAI Health Policy Statement on Integrating the Healthcare Enterprise. *J Am Coll Cardiol*.2016;68(12):1348-1364. doi:10.1016/j.jacc.2016.04.017.
44. **Edward T. A. Fry**, Mary Norine Walsh. Cardiovascular Health System Leadership: An Evolving Model. Journal American College of Cardiology.2018;71(5):575-576. doi: 10.1016/j.jacc.2017.12.039
45. Monteleone, Peter P., Subhash Banerjee, Priya Kothapalli, Ariel Dora Stern, Daniel Fehder, Ron Ginor, Dominic Vollmar, **Edward T. A. Fry**, and Mark J. Pirwitz. The Market Reacts Quickly: Changes in Paclitaxel Vascular Device Purchasing Within the Ascension Healthcare System. *Journal of Invasive Cardiology*.2019;32(1):18-24.
46. Benjamin IJ, Valentine CM, Oetgen WJ, Sheehan KA, Brindis RG, Roach WH Jr, Harrington RA, Levine GN, Redberg RF, Broccolo BM, Hernandez AF, Douglas PS, Piña IL, Benjamin EJ, Coylewright MJ, Saucedo JF, Ferdinand KC, Hayes SN, Poppas A, Furie KL, Mehta LS, Erwin JP 3rd, Mieres JH, Murphy DJ Jr, Weissman G, West CP, Lawrence WE Jr, Masoudi FA, Jones CP, Matlock DD, Miller JE, Spertus JA, Todman L, Biga C, Chazal RA, Creager MA, **Fry ET**, Mack MJ, Yancy CW, Anderson RE. 2020 American Heart Association and American College of Cardiology Consensus Conference on Professionalism and Ethics: a consensus conference report. *J Am Coll Cardiol* 2021;77:3079-3133.
47. **Fry ETA**. Care Transformation: It Is Our Mission. *J Am Coll Cardiol*. 2022;79:1636–1638.
48. **Fry ETA**. Resigned to the “Great Resignation?”. *J Am Coll Cardiol*. 2022;79:2463–2466.
49. **Fry ETA**. Gun Violence: Yes, This Is Our Lane. *J Am Coll Cardiol*. 2022;80:646–648.
50. **Fry ETA**, Walsh MN, Wood MJ. Maternal Health: The Heart of the Matter. *J Am Coll Cardiol*. 2022;80:1107–1109.
51. **Fry ETA**, Jones SO, Morse N. ACC Advocacy: Engage, Influence, Advocate. *J Am Coll Cardiol*. 2022;80:1844-1847.
52. **Fry ETA**. Trust Me, I'm a Doctor. *J Am Coll Cardiol*. 2022;81:97-99..
53. Bowman L, Weidinger F, Ablert MA, **Fry ETA**, Pinto FJ. Randomized Trials Fit for the 21st Century: A Joint Opinion from the European Society of Cardiology, American Heart Association, American College of Cardiology, and the World Heart Federation. *J Am Coll Cardiol*. 2022;81:1205-1210.
54. **Fry ETA**. Too Much, Too Little, Too Late. *J Am Coll Cardiol* 2023;81:842-844.

55. **Fry ETA**, Kuvin J, Sibley J. Maintenance of Competence in Cardiovascular Practice: Time for More Learning, Less Testing. *J Am Coll Cardiol.* 2023;81:924-927
56. **Fry ETA**, Pineiro DJ. One World, One Heart. *J Am Coll Cardiol.* 2023;81:1211-1213.
57. **Fry ETA**, Maddox TM, Bhatt AB. Innovation in Cardiovascular Care Delivery. *J Am Coll Cardiol.* 2023;81:2207-2209.
58. Maddox TM, **Fry ETA**, Wilson BH. The Cardiovascular Workforce Crisis: Navigating the Present, Planning for the Future. *J Am Coll Cardiol.* 2024;83:466-469.
59. **Fry ETA**. Private Equity in Cardiovascular Practice: Solution or Symptom? *J Am Coll Cardiol.* 2024;84:957-959.
60. Dhramakumar R, Kloner RA, Fishbein M, Heusch G, Vora KP, Gropler R, Henry T, Shing-Chan F, Singh D, Jambunathan N, Subramanian R, Kreutz RP, Reed GW, Kovacs RJ, **Fry ETA**, Kalra A, Kumar A, Raman SV. Reperfused Myocardial Infarction: The Road to CCS Classification of Acute MI and Beyond (State-of-the-Art Review). *JACC Adv.* 2025 Feb. 4(2) 101636.
61. Osude N, Van Spall H, Bosworth H, Krychtiuk K, Spertus J, Fatoba S, Fleischer L, **Fry ETA**, Green J, Greene S, Ho M, Jackman J, Leopold J, Magwire M, McGuire D, Mansah G, Tuttle KR, Willey V, Pagidapati N, Granger C. The Advancement of the Implementation of Evidenced-Based Therapies for Cardiovascular-Kidney-Metabolic Conditions: A Multi-Stakeholder Perspective. *Am Heart J* 2025;286 (August 2025):18–34. <https://doi.org/10.1016/j.ahj.2025.03.005>.
62. Kramer CM, **Fry ETA**, Morris PB. Calling All Geniuses. *J Am Coll Cardiol.* 2026;87:566-569.

Book Chapters / Monographs

1. **Fry ETA**. Medical evaluation and recipient selection for heart and heart-lung transplantation. In, *Manual of Transplantation*. Edited by L Makowka. Austin, Texas, R.G. Landes, 1992.
2. Kelly DP, **Fry ETA**. Heart failure. In, *Manual of Medical Therapeutics*. Edited by A Whelan, A Woodley. Boston, Little Brown and Co, 1992.
3. Waller BF, Orr CM, Pinkerton CA, Slack JD, VanTassel JW, Peters T, **Fry ET**. Balloon angioplasty restenosis. Intimal proliferation and chronic elastic recoil. In, *Interventional Radiology*. Edited by WR Castaneda-Zuniga. 3rd ed. Vol 1. Baltimore, Williams & Wilkins, 1997.

4. JB Hermiller, **ET Fry**, T Peters, CM Orr, J Van Tassel, CA Pinkerton. Quantitative and Qualitative Coronary Angiography. Vascular Diagnostics 1994.
5. **Fry ETA**, Hermiller JB, Pinkerton CA. New intracoronary stent designs: form follows function versus function follows form. Current Opinion in Cardiol. 13:232-239, 1998
6. **Fry ETA**, Lloyd-Jones D. Foreword: Cardiological Society of India (CSI) Update Book 2022 (in press).

ABSTRACTS

1. **Fry ETA**, Lucore, CL, Sobel BE. Biological effects of t-PA glycosylation. Circulation 76 (suppl IV):152, 1987.
2. **Fry ETA**, Sobel BE. Heparin does not interfere with binding of t-PA to thrombi or with thrombolysis. Circulation 76 (suppl IV):211, 1987.
3. Grace AM, **Fry ETA**, Sobel BE. Decreased aggregation of platelets induced by exposure to pharmacologic concentrations of t-PA in whole blood. Circulation 70 (suppl IV):307, 1987.
4. **Fry ETA**, Mack DL, Sobel BE. Synergistic thrombolysis in vitro with t-PA and scu-PA. Clin Res 36:363A, 1988.
5. Broeze R, Mao J, **Fry ETA**, Fujii S, Sobel B, Socolow J, Abercrombie D, Buchinski B, Hsiao K, Stump D, Vovis G. Biological characterization of fully glycosylated recombinant scu-PA. Fibrinolysis 2 (suppl 1):65, 1988.
6. **Fry ETA**, Fujii S, Mack DL, Monge JC, Billadello JJ, Sobel BE. Specific labeling of human thrombi with an inactive mutant of t-PA in vitro (abstract). Circulation 80 (suppl II):2054, 1989.
7. Sobel BE, Nachowiac DA, **Fry ETA**, Bergmann SR. The dependence of the efficacy of fibrinolytic agents on clot selectivity. Circulation 80 (suppl II):128, 1989.

8. Nachowiak DA, **Fry ETA**, Fujii S, Sobel BE. Retardation of clot lysis by plasminogen steal (abstract). *Circulation* (AHA Scientific Sessions) 1990.
9. Lindsay BD, Osborn JL, **Fry ETA**, Kenzora JL, Ambos HD, Cain ME. Prospective detection of vulnerability to sustained ventricular tachycardia in patients awaiting cardiac transplantation (abstract). *Circulation* (AHA Scientific Sessions) 1990.
10. **Fry ET**, Hermiller JB, Peters TF, Orr CM, VanTassel J, Ness B, Pinkerton CA. Risks, treatment, and outcome of acute stent closure (abstract). *Circulation* 90:I-650, 1994.
11. Hermiller JB, **Fry ET**, Peters TF, Orr CM, VanTassel J, Pinkerton CA. Multiple Gianturco-Roubin stents for long dissections causing acute and threatened coronary artery closure (abstract). *J Am Coll Cardiol* 23:73A, 1994.
12. McCallister SH, Hermiller JB, Lips DL, **Fry ETA**, Landin RJ, Pinkerton CA, Linnemeier TJ, Indiana Heart Institute. Femoral venous access during angioplasty: justified or not? (abstract) *J Am Coll Cardiol* 23:402A, 1994.
13. Hermiller JB, **Fry ET**, Berkompas DC, Saltiel FS, Peters TF, Ness BK, Orr CM, VanTassel J, Pinkerton CA. Five year clinical follow-up of Gianturco-Roubin stent. No late stent restenosis (abstract). *Circulation* 92:I-280, 1995.
14. Hermiller JB, **Fry ET**, Peters TF, Orr CM, VanTassel J, Ness B, Pinkerton CA. Late lesion regression within the Gianturco-Roubin flex-stent (abstract). *J Am Coll Cardiol* 25:375A, 1995.
15. Leon MB, **Fry ETA**, O'Shaughnessy CD, Yakubov SJ, Carrozza JP, Kereiakes DJ, Popma JJ, Warth DC, Thompson MA, Rogers EW, Dean LS, Pinkerton CA. Preliminary multicenter experiences with the new GR-II stent for abrupt and threatened closure syndrome (abstract). *Circulation* 94(suppl I):I-207, 1996.
16. **Fry ETA**, Hermiller JB, Berkompas DC, Saltiel FS, Peters TF, Orr CM, VanTassel J, Waller BF, Pinkerton CA. Coronary stenting without coumadin improves outcomes, decreases complications, and reduces costs (abstract). *J Invasive Cardiol* 8:44, 1996.
17. **Fry ETA**, Hermiller JB, Berkompas DC, Saltiel FS, Peters TF, Orr CM, VanTassel J, Waller BF, Pinkerton CA. "Hybrid" stenting: use of contiguous stents of differing design for multiple stent deployment (abstract). *J Invasive Cardiol* 8:44, 1996.

18. **Fry ETA**, Hermiller JB, Lips DL, Hodes ZI, Linnemeier TJ, Heimansohn DA, Matheny RG, Pinkerton CA. Comparison of stents, bypass surgery (CABG), and minimally invasive bypass (MICAB) for isolated LAD revascularization: patient selection, outcomes, and cost (abstract). *Circulation* 94(suppl I):I-324, 1996.
19. **Fry ETA**, Hermiller JB, Peters TF, Orr CM, VanTassel J, Berkompas DC, Saltiel FS, Ernst C, Erner B, Waller BF, Pinkerton CA. Is ACC/AHA lesion classification predictive of successful coronary intervention in the era of new devices (abstract)? *J Am Coll Cardiol* 27(suppl A):152, 1996.
20. **Fry ETA**, Hermiller JB, Peters TF, Orr CM, VanTassel J, Waller BF, Pinkerton CA. Stenting of coronary bypass grafts without coumadin: long-term outcome (abstract). *European Heart Journal* 17(suppl):459, 1996.
21. **Fry ETA**, Hermiller JB, Peters TF, Saltiel FS, Berkompas DC, Orr CM, VanTassel J, Pinkerton CA. Comparison of Gianturco-Roubin (GR) and Palmaz-Schatz (PS) coronary stenting: angiographic results, in-hospital events, and 6 month outcomes (abstract). *J Invasive Cardiol* 8:44, 1996.
22. **Fry ETA**, VanTassel J, Hermiller JB, Pinkerton CA. Early sheath removal and ambulation post stenting using the Prostar Percutaneous Vascular Surgical device (abstract). *J Invasive Cardiol* 8:45, 1996.
23. Hermiller JB, **Fry ETA**, Berkompas DC, Saltiel FS, Peters TF, Ness BK, Orr CM, VanTassel J, Pinkerton CA. Optimal high-pressure stenting without coumadin: six month clinical outcome (abstract). *J Invasive Cardiol* 8:47, 1996.
24. Hermiller JB, **Fry ETA**, Berkompas DC, Saltiel FS, Peters TF, Ness BK, Orr CM, VanTassel J, Pinkerton CA. Stenting attenuates the negative impact of age on percutaneous coronary intervention: equivalent results in young and old (abstract). *J Invasive Cardiol* 8:46, 1996.
25. Hermiller JB, **Fry ETA**, Berkompas DC, Saltiel FS, Peters TF, Orr CM, VanTassel J, Pinkerton CA. Effect of gender on acute outcome following intracoronary bailout stenting (abstract). *J Invasive Cardiol* 8:47, 1996.
26. Nasser TK, **Fry ETA**, Peters TF, VanTassel J, Orr CM, Annan K, Khatib Y, Waller BF, Pinkerton CA, Hermiller JB. In-hospital and interim clinical outcomes of coronary stents in the elderly (abstract). *J Am Coll Cardiol* 29:72A, 1997.
27. Nasser TK, **Fry ETA**, Peters TF, VanTassel J, Orr CM, Khatib Y, Annan K, Branyas NA, Pinkerton CA, Hermiller JB. Coronary stenting in women:

- clinical outcomes are equivalent to men (abstract). *J Am Coll Cardiol* 29:71A, 1997.
28. O'Shaughnessy CD, Popma JJ, Dean LS, **Fry ETA**, Carrozza JP, Knopf WD, Kereiakes DJ, George BS, Thompson MA, Brinker JA, Raizner AE, Leon MB. The new Gianturco-Roubin coronary stent is an improved therapy for abrupt and threatened closure syndrome (abstract). *J Am Coll Cardiol* 29:416A, 1997.
 29. Leon MB, Popma JJ, O'Shaughnessy C, Dean LS, Lansky AJ, **Fry ETA**, Curran MJ. Quantitative angiographic outcomes after Gianturco-Roubin II stent implantation in complex lesion subsets (abstract). *Circulation* 96:I-653, 1997.
 30. Makkar R, Eigler N, Goff B, **Fry E**, Barr L, D'Haem C, Fischell T, Litvack F. Primary reperfusion in acute myocardial infarction with ReoPro and heparin: interim results of ReoMi pilot study (abstract). *J Am Coll Cardiol* 31:94A, 1998.
 31. Zidar JP, O'Shaughnessy CD, Dean LS, Holmes DR, Moore PB, Rogers EW, **Fry ET**, Raizner AE, Voorhees WD, Leon MB. Elective GRII stenting in small vessels: multicenter results (abstract). *J Am Coll Cardiol* 31:274A, 1998.
 32. Lansky AJ, Popma JJ, Hanzel GS, Curran MJ, Dean L, **Fry E**, Fearnott N, Abizaid AS, Thompson C, Kerr JL, Merritt AJ, Leon MB. Predictors of late clinical outcome after Gianturco-Roubin II stent use. Final results of the GRII randomized clinical trial (abstract). *Circulation* 98: (suppl): I-662, 1998
 33. Alexndra JL, Pompa JJ, Hanzel GS, Curran MJ, Dean L, **Fry E**, Ebizaid AS, Thompson C, Kerr JL, Merritt AJ, Leon MB. Predictors of late clinical outcome after Gianturco-Roubin II stent use. Final results of the GR II randomized clinical trial. *Circulation* 98(suppl):1-662, 1998
 34. Zidar J, Batchelor W, Berger PB, Deutsch E, **Fry E**, Teirstein PS, Ross AM, Mahaffey KW, Meier SJ, Tipping DM, Berkowitz SD. Does the lowmolecular-weight heparin enoxaparin reduce stent thrombosis in high-risk stent patients? Results from ATLAST trial: Enoxaparin plus antiplatelet therapy vs. antiplatelet alone in patients at increased risk of stent thrombosis (abstract). *Circulation* 100(suppl):I-380, 1999.
 35. Kereiakes D, **Fry E**, Lengerich R, Howard W, Anderson L, Broderick T, Shimshak T, Roth E, Whang D, Schneider J, Hattemer C, Runyon JP, Abbottsmith C. Abciximab associated thrombocytopenia is reduced by enoxaparin: preliminary results of the NICE 4 trial. *Am J Cardiol* 1999; 84:67P.

36. Kerieakes D, **Fry E**, Matthai W, Barr L, Niederman A, Brodie B, Basale P, Cohen M, Zidar J, Lengerich R, Howard W, Anderson L. Safety of enoxaparin-abciximab combination for percutaneous coronary intervention: preliminary results of the NICE 4 trial. *Am J Cardiol* 1999;84:67P
37. Savage MP, Fischman DL, Faiza K, **Fry ETA**, Kiernan FJ, Goldberg S. A randomized comparison of elective stenting and balloon angioplasty in the treatment of small coronary arteries (abstract). *J Invas Cardiol* 2000;12(suppl):I-503, 1999.
38. Kereiakes DJ, **Fry E**, Matthai W, Niederman A, Barr L, Brodie B, Zidar J, Casale P, Christy G, Moliterno D, Lengerich R, Broderick T, Shimshak T, Cohen M. Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: "Nice guys finish first" (abstract). *J Invas Cardiol* 2000;12(suppl A):1A-5A
39. Kereiakes DJ, Grines C, **Fry E**, Barr L, Matthai W, Broderick TM, Lengerich R, Cohen M, Esente P. Abciximab-enoxaparin interaction during percutaneous coronary intervention: Results of the NICE 1 and 4 trials. *J Am Coll Cardiol* 2000;35:92A
40. Kereiakes D, Grines C, **Fry E**, et al. Combination enoxaparin and abciximab during percutaneous coronary intervention: A new standard of Care? *Current Interventional Cardiology Reports* 2000;2:157-163.
41. Chesebro James H, Freek W.A, Verheugt, Kontny, Frederick, **Fry Edward**, Wallentin, Lars, Camm, A. John, Bechtold, Heinrich. Evaluating the Place of Low-Molecular-Weight Heparin in the Management of Acute Coronary Syndromes. *Clinical Cardiology* 2001 Vol.24 (Suppl.I), I-20-1-22
42. Kambeez Berenji, Sai Devarapalli, **Edward Fry**, James B. Hermiller: Late Stent thrombosis: Report of 17 cases of documented late stent. *Catheterization & Cardiovascular Interventions* Vol. 69 / Issue 6, May 1, 2007
43. Kambeez Berenji, **Edward Fry**, Polly Moore, Rebecca Joest, Sandra Berney, Michellene Clements, David Heimansohn, Mary Walsh: Coronary Stenting in Cardiac transplant vasculopathy. *Catheterization & Cardiovascular Interventions* Vol. 69 / Issue 6, May 1, 2007
44. Cost-Effectiveness Comparison of Radial and Femoral Percutaneous Coronary Intervention in a Large Multi-State Health System. Angela Winegar, Allison J. Ottenbacher, Thomas P. Erlinger, Joseph, Wallace, Annie E. Cacchione, RenHuai Huang, Angelo Bufalino, Kevin Willmann, **Edward T.A. Fry**, Joseph G. Cacchione. *Journal of the American College of Cardiology* March 24, 2020, 75 (11 Supplement 1) 1370; DOI: 10.1016/S0735-1097(20)31997-5

CLINICAL RESEARCH

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of the ACAT Inhibitor CS-505 for Reducing the Progression of Atherosclerosis in Subjects with Coronary Artery Disease using Intravascular Ultrasound (IVUS) – Protocol #505-202 (ACTIVATE) (Site Sub-Investigator)

Proximal Protection during Saphenous Vein Graft Intervention Using the Proxis Embolic Protection System: A Randomized, Prospective, Multicenter, Clinical Trial (Site Sub-Investigator)

BLAZE - EmBoLic Protection TrAnsluminally with the FilterWire EZ DEvice in Saphenous Vein Grafts (Site Sub-Investigator)

FilterWire™ during Transluminal Intervention of High Risk Saphenous Vein Grafts (Site Sub-Investigator)

X-TRACTION: X-SIZER® Treatment for Reduction in Angiographically Confirmed Thrombus and Infarction OccurreNce (Site Principal Investigator)

X-TRACT - X-SIZER™ for Treatment of Thrombus and Atherosclerosis in Coronary Interventions Trial – AMI Registry (Site Principal Investigator)

X-TRACT - X-SIZER™ for Treatment of Thrombus and Atherosclerosis in Coronary Interventions Trial (Site Principal Investigator)

A Phase IIIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety, Efficacy and Tolerability of Fenoldopam Mesylate in Subjects Undergoing Interventional Cardiology Procedures (Site SubInvestigator)

A Three-Arm Double-Blind, Randomized Comparator Study Comparing the Renal Effects of Visipaque® 320 (iodixanol) with Placebo vs. Visipaque® 320 (iodixanol) with Acetylcysteine vs. Optiray® 320 (ioversol) with Acetylcysteine in

Chronic Stable Renal Failure Subjects Undergoing Coronary Angiography/Interventions (Site Sub-Investigator)

TherOx® AO System AMIHOT Phase II Trial; A Randomized, Controlled, Multicenter Trial of Aqueous Oxygen Infusion for 90 Minutes Post Primary PTCA/Stent Intervention in Acute Myocardial Infarction Patients (Site SubInvestigator)

A Multicenter Evaluation of the Rapidpoint ENOX Monitoring System Among Percutaneous Coronary Intervention Patients Receiving Enoxaparin (The ELECT study: EvaLuating ENOX Clotting Times); Protocol #: CT0055.01 (Site SubInvestigator)

A Multicenter Trial of Localized Radiation Therapy to Inhibit Restenosis, #P005501 (GAMMA V) (Site Sub-Investigator)

The TRAP Vascular Filtration System (Site Sub-Investigator)

The VICC Trial: **V**isipaque (Iodixanol) v. **I**sovue (Iopamidol) in **C**ardiac **C**atheterization. A Phase IV Prospective, Randomized, Multi-Center Trial of Visipaque vs. Isovue in Interventional Cardiac Catheterization (Sponsor Protocol # 16,272-59) (Site Sub-Investigator)

TARGET A randomized, multicenter, double-blind, Abciximab in patients undergoing Percutaneous Coronary Intervention with Intracoronary Stent Placement (Site Sub-Investigator)

PENTA Registry: A Non-Randomized Evaluation of the Multi-Link Rx PENTA Coronary Stent System in the Treament of Patients with de novo Native Coronary Artery Lesions (Site Sub-Investigator)

Frontrunner Percutaneous Coronary Catheter Chronic Total Occlusion (CTO) Clinical Study (DVT 110 Rev A 10/26/00) (Site Sub-Investigator)

FilterWire - FilterWire During Transluminal Intervention of Saphenous Vein Grafts - Randomized Multi-Center Clinical Trial (Site Sub-Investigator)

TAXUS IV: Paclitaxel-Eluting Coronary Stent System in In-Stent Restenosis (Site Sub-Investigator)

Pre-CHILL Study: Cryoplasty Hyperplasia Inhibition Prevents Late Loss Feasibility Study (Site Sub-Investigator)

VISION - Multi-Link VISION Registry: A Non-Randomized Evaluation of the Multi-Link Rx VISION™ Coronary Stent System in the Treatment of Patient with de novo Native Coronary Artery Lesions (Site Sub-Investigator)

VICTORY- Elective and Acute Stenting of Coronary Arteries On Express System (Site Sub-Investigator)

LuMend Frontrunner™ Chronic Total Occlusion Revascularization (CROSS) Registry (Site Sub-Investigator)

Cooling as an Adjunctive Therapy to Percutaneous Intervention in Patients with Acute Myocardial Infarction (50-0045) (Site Sub-Investigator)

Complex Bifurcation Atherectomy Trial (COMBAT): A Non-Randomized Registry Study Using the FOXHOLLOW Coronary Debulking Catheter in the Treatment of Bifurcation Lesions in Native Coronary Arteries (Site Sub-Investigator)

Feasibility IDE: Lowering Adverse Outcomes with Temperature Regulation (LOWTEMP) (Site Sub-Investigator)

A Prospective, Multicenter, Non-Randomized Study to Evaluate the Safety and Efficacy of the SLK- View™ Side-Access Coronary Stent. (Site Sub-Investigator)

NIRFLEX™ U.S. Clinical Study (Site Sub-Investigator)

CVSi Peripheral Balloon Catheter System Safety Registry Protocol (Site SubInvestigator)

Medtronic AVE S8 DeNovo and Restenotic Registry (Site Sub-Investigator)

ARISE: Aggressive Reduction of Inflammation Stops Events Reduction of Vascular Inflammation and Coronary Atherosclerosis, with AGI 1067, a VProtectant, Reduces Cardiovascular Events in Patients with Coronary Artery Disease (Protocol # AGI-1067-042) (Site Sub-Investigator)

The Assessment of the Medtronic AVE Interceptor Saphenous Vein Graft Filter System (AMEthyst) (Site Sub-Investigator)

SPIDER™ Distal Embolic Protection Device Trial (Site Principal Investigator)

A Double-Blind, Randomized, Multicenter, Dose-Ranging Trial of CS-747 (LY640315) Compared with Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (JUMBO—Joint Utilization of Medications to Block

Platelets Optimally—TIMI 26) (Site Sub-Investigator)

A Randomized Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Stent System versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions (Site Sub-Investigator)

Medtronic AVE Micro-Driver Registry (Site Sub-Investigator)

An Evaluation of the Multi-Link Rx VISION™ SVS Coronary Stent System in the Treatment of Patients with Abrupt or Threatened Abrupt Closure of de Novo or Restenotic Lesions In Native Lesions in Native Coronary Arteries or Arterial Bypass Graft Conduits (VISION™ SVS Registry) PROTOCOL 01-342 (Site Sub-Investigator)

AngioJet Rheolytic Thrombectomy In Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction (AIMI) (Site Sub-Investigator)

REPLACE 2: Randomized Evaluation in Percutaneous Coronary Intervention Linking Angiomax to reduced Clinical Events (Protocol No. TMC-BIV-00-01) (Site Sub-Investigator)

PROVE IT - Provastatin or Atorvastatin Evaluation and Infection Therapy (Site Principal Investigator)

An International, Randomized, Double- Blind Study Evaluating the Efficacy and Safety of Fondaparinux versus Enoxaparin in the Acute Treatment of Unstable Angina / Non ST-Segment Elevation MI Acute Coronary Syndromes (OASIS 5-Michelangelo; Protocol # EFC3197) (Site Sub-Investigator)

A Randomized Trial to Evaluate the Relative Protection against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia among Anti-Platelet and AntiThrombotic Agents (PROTECT – TIMI 30; PROTOCOL 03-046) (Site Sub-Investigator)

The FiLterWire EZ™ System Used in the Treatment of an Acute Myocardial Infarction for Embolic Protection; A Prospective, Multi-Center, Randomized Study (FLAME) (Site Sub-Investigator)

A Double Blind Randomized Trial of Clopidogrel 300 mg Loading Dose & Aspirin 325mg Followed By Clopidogrel 75mg & Aspirin Daily Compared with Placebo Loading Dose & Aspirin 325 mg Followed By Clopidogrel 75 mg & Aspirin Daily For The Prevention Of Vascular Events And All-Cause Mortality In Patients Undergoing Percutaneous Coronary Intervention (CREDO; Ptcl. No. EFC 7086) (Site Principal Investigator)

CardioShield Application Protects during Transluminal Intervention of Vein Grafts by Reducing Emboli (CAPTIVE Pivotal Trial)(Site Sub- Investigator)

In-Stent Restenosis (In-Stent Patency) Treated with a Cook Inc. Paclitaxel-Coated LOGIC™ Coronary Stent (Site Sub- Investigator)

(PEPCI) Pharmacokinetic study of enoxaparin in patients undergoing percutaneous coronary intervention (8-12 hrs after subcutaneous injection) (Site Sub-Investigator)

An International Phase 2-3, Stratified, Randomized, Open-Label, Parallel-Group Clinical Trial to Evaluate the Safety and Efficacy of a Single Intravenous Bolus of enoxaparin versus Intravenous Unfractionated Heparin in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention; (STEEPLE Study); XRP4563/4001 (Site Sub-Investigator)

The ACUTY Trial: A randomized comparison of Angiomax[®] (bivalirudin) versus Lovenox[®]/Clexane[®] (enoxaparin) in patients undergoing early invasive management for acute coronary syndromes without ST-segment elevation (Protocol No. TMC-BIV-02-08, US IND NO. 35,756) (Site Sub-Investigator)

SIRIUS: A Multicenter, Randomized, Double Blind Study of the SIROLIMUS-coated BX VELOCITY™ BALLOON-EXPANDABLE STENT in the Treatment of Patients with DE NOVO Coronary Artery Lesions (Site Sub-Investigator)

Stents Used in De-Novo lesions (length <30 mm) in Native Coronary Arteries with a Reference Vessel Diameters Ranging from 2.5 mm to 5.0 mm (LOGIC) (Site Sub-Investigator)

SEPIA-ACS 1/TIMI 42 - DRI6624: A Randomized, double-blind, triple-dummy, dose-ranging study, including an active control of unfractionated heparin and eptifibatide, to evaluate the clinical efficacy and safety of otamixaban, in patients with non-ST elevation acute coronary syndrome and planned early invasive strategy (Site Sub-Investigator)

SEPIA PCI; XRP0673A/2002; A multinational, randomized, double-blind, double-dummy, exploratory, parallel-group, dose-ranging, phase II Study to Evaluate the Pharmacodynamics, the safety and tolerability, and pharmacokinetics of several Intravenous regimens of the factor Xa inhibitor otamixaban (XRP0673), in comparison to intravenous unfractionated heparin, in subjects undergoing nonurgent Percutaneous Coronary Intervention (Site Sub-Investigator)

A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of Pexelizumab in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention APEX AMI (Assessment of PEXelizumab in Acute Myocardial Infarction); Protocol #2003056 (Site SubInvestigator)

Osiris Protocol No. 401: A phase 1 randomized, double-blind, placebocontrolled, dose-escalation study to determine the safety of intravenous ex-vivo cultured adult human mesenchymal stem cells (Provacel™) following acute myocardial infarction (Site Sub-Investigator)

A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary Intervention/TIMI-38 (Site Principal Investigator)

CHAMPION PCI: A Clinical Trial Comparing Cangrelor to Clopidogrel in Subjects who Require Percutaneous Coronary Intervention (Site Sub-Investigator)

Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST elevation Acute Coronary Syndromes (MERLIN) – TIMI 36 (CVT-3036) A randomized, double-blind, parallel-group, placebo-controlled, multinational, clinical study to evaluate the efficacy and safety of ranolazine versus placebo in patients with non-ST segment elevation acute coronary syndromes (Site Principal Investigator)

SPIRIT III Clinical Trial: A Clinical Evaluation of the XIENCE™ V Everolimus Eluting Coronary Stent (EECS) System in the Treatment of Subjects with de novo Native Coronary Artery Lesions (Protocol # 03-360) (Site Sub-Investigator)

SPIRIT IV Clinical Trial: A Clinical Evaluation of the XIENCE™ V Everolimus Eluting Coronary Stent System (EECSS) in the Treatment of Subjects with de novo Native Coronary Artery Lesions (SPIRIT IV ClinicalTrial; Protocol Number: 05-368) (Site Sub-Investigator)

COSTAR II: CObalt chromium STent with Antiproliferative for Restenosis II Trial (Site Sub-Investigator)

IMPROVE IT; IMProved Reduction of Outcomes: Vytorin Efficacy International Trial; Protocol P04103 (Site Principal Investigator)

A Randomized Controlled Trial to Evaluate the Safety and Efficacy of theZoMaxx™ Drug Eluting Coronary Stent System as compared to the Taxus™ Express 2™ Paclitaxel-Eluting Stent in de novo Coronary Arterial Lesions;

Protocol #640-0048-02 (ZoMaxx II Trial) (Site Sub-Investigator)

A Randomized Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Stent System versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions (ENDEAVOR III) (Site SubInvestigator)

Treatment of De Novo Coronary Disease Using the TAXUS Liberté-SR Paclitaxel-Eluting Stent (TAXUS ATLAS LONG LESION) (Site Sub-Investigator)

Treatment of De Novo Coronary Disease Using the TAXUS Liberté-SR Paclitaxel-Eluting Stent (TAXUS ATLAS SMALL VESSEL) (Site Sub-Investigator)

TAXUS ATLAS: A Multi-center, single-arm study of the TAXUS Liberte™ SR stent for the treatment of patients with de novo coronary artery lesions (Site SubInvestigator)

Direct Stent Treatment of De Novo Coronary Disease Using the TAXUS Liberté-SR Paclitaxel-Eluting Stent (Site Sub-Investigator)

A Randomized, Controlled Trial of the Medtronic ENDEAVOR Drug (ABT-578) Eluting Coronary Stent System vs. the TAXUS™ Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions (ENDEAVOR IV) (Site Sub-Investigator)

Direct Inhibition of δ Protein Kinase C Enzyme to Limit Total Infarct Size in Acute Myocardial Infarction (DELTA MI): Intracoronary KAI-9803 for Injection as an Adjunct to Primary Percutaneous Coronary Intervention for Acute ST-Elevation Myocardial Infarction (Site Sub-Investigator)